3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
42
Lymphoma, Follicular
31
Lymphoma, Mantle-Cell
22
Lymphoma, B-Cell, Marginal Zone
17
Lymphoma, Large B-Cell, Diffuse
15
Lymphoma
13
Lymphoma, Non-Hodgkin
9
Lymphoma, B-Cell
8
Neoplasms
6
Leukemia, Hairy Cell
4
Leukemia, B-Cell
4
Neoplasm, Residual
3
Leukemia
3
Waldenstrom Macroglobulinemia
2
Recurrence
2
Disease
2
Dendritic Cell Sarcoma, Interdigitating
2
Burkitt Lymphoma
2
Mycosis Fungoides
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Leukemia, Prolymphocytic, B-Cell
1
Indolent Non-Hodgkin's Lymphoma
1
Indolent Non-Hodgkin Lymphoma
1
Hodgkin Disease
1
Carcinoma, Transitional Cell
1
Breast Neoplasms
1
Anemia
1
Interventions
obinutuzumab
1
Rituximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Indolent Non-Hodgkin's Lymphoma
×
obinutuzumab
×
Clear all
NCT01889797
2017-05-05
PrE0401
PrECOG, LLC.
Phase 2
Terminated
32 enrolled
14 charts